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The structures of acetylcholine-binding protein
(AChBP) and nicotinic acetylcholine receptor (nAChR)
homology models have been used to interpret data from
mutagenesis experiments at the nAChR. However, little
is known about AChBP-derived structures as predictive
tools. Molecular surface analysis of nAChR models has
revealed a conserved cleft as the likely binding site for
the 4/7 -conotoxins. Here, we used an 32 model to
identify 2 subunit residues in this cleft and investi-
gated their influence on the binding of -conotoxinsMII,
PnIA, and GID to the 32 nAChR by two-electrode volt-
age clamp analysis. Although a 2-L119Q mutation
strongly reduced the affinity of all three -conotoxins,
2-F117A, 2-V109A, and 2-V109Gmutations selectively
enhanced the binding of MII and GID. An increased
activity of -conotoxins GID and MII was also observed
when the 2-F117A mutant was combined with the 4
instead of the 3 subunit. Investigation of A10L-PnIA
indicated that high affinity binding to 2-F117A, 2-
V109A, and 2-V109G mutants was conferred by amino
acids with a long side chain in position 10 (PnIA num-
bering). Docking simulations of 4/7 -conotoxin binding
to the 32 model supported a direct interaction be-
tween mutated nAChR residues and -conotoxin resi-
dues 6, 7, and 10. Taken together, these data provide
evidence that the  subunit contributes to -conotoxin
binding and selectivity and demonstrate that a small
cleft leading to the agonist binding site is targeted by
-conotoxins to block the nAChR.
Neuronal nicotinic acetylcholine receptors (nAChRs)1 com-
prise a large family of ion channels formed by the heteropen-
tameric assembly of homologous subunits. -Conotoxins, small
disulfide-rich peptides isolated from the venom of predatory
cone snails, potently and selectively block nAChRs (1). They act
as competitive antagonists at the ACh binding site, which is
formed at the interface between neighboring subunits. These
-conotoxins can distinguish between muscle and neuronal
nAChRs subtypes and even between different binding sites
within the same receptor. As a result, they are widely used as
pharmacological tools for the subtype differentiation of
nAChRs in native tissues (2).
The 4/7 (4 residues in loop 1 and 7 in loop 2) -conotoxins are
of particular interest given their ability to discriminate be-
tween diverse neuronal - nAChR subunit combinations. For
example, MII was found to be selective for the 3 and especially
the 6 subunit containing nAChRs (3, 4) and aided the identi-
fication of the nAChR subunit composition in monkey striatum
implicated in Parkinson disease (5, 6). The 4/7 -conotoxin
PnIA preferentially blocks 32 but also 7 rat nAChRs (7, 8),
whereas -GID potently blocks 7 and 32 nAChRs but also
acts at 42 nAChR at higher concentrations (9). MII, PnIA,
and GID share an identical backbone structure common to all
4/7 -conotoxins investigated (9–11). Therefore, their specific
selectivities are thought to arise from their different amino acid
side chains. As a consequence, understanding the molecular
determinants of their interaction with the receptor may help in
the design of optimized pharmacological tools for the nAChRs
with novel or improved selectivities. However, the lack of de-
tailed information on the three-dimensional structure of the
-conotoxin binding site has hampered such projects.
The acetylcholine-binding protein (AChBP) crystal structure
solved by Sixma and colleagues (12) recently provided a tem-
plate to create homology models of the ligand binding domain of
receptor members of the Cys-loop ligand-gated ion channels
family. Homology models of the ligand binding domain of 7,
32, 34, and 42 nAChR subtypes are already providing
useful insights into ligand-receptor interactions at the molec-
ular level (13–16). Our previous docking simulations of -cono-
toxins ImI and PnIB on an 7 nAChR homology model revealed
that these two peptides target a small cleft forming one of two
possible entrances to the ACh binding site (17). We could also
identify an equivalent cleft on an 32 model as the likely
region of the 32 nAChR targeted by these peptides. Upon
examination of this model, it was apparent that the 2 subunit
contributed more than the  subunit to the formation of this
cleft, suggesting an important role of -residues for binding
and/or selectivity. In this study, we mutated three residues in
the 2 subunit residues located in this cleft to characterize the
contribution of the  subunit to -conotoxin binding. Each of
these mutants influenced the binding of -conotoxins MII, GID,
and PnIA. Additionally, molecular surface analysis revealed
striking shape complementarity between the highly conserved
N-terminal half of the 4/7 -conotoxins structure and the cleft.
Finally, docking experiments showed that both MII and PnIA
bind deep into the 32 nAChR cleft, explaining at the molec-
ular level the experimental results obtained from mutagenesis
studies. Based on these results, we propose that the conserved
cleft above the 910 hairpin is the binding site for 4/7 -cono-
toxins active at 7, 32, and 42 nAChRs and that the
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differences in the cleft residues provide the determinants di-
recting -conotoxin selectivity.
EXPERIMENTAL PROCEDURES
Materials—cDNAs encoding neuronal nAChRs were provided by J.
Patrick (Baylor College of Medicine, Houston, TX) and subcloned into
the oocyte expression vector pNKS2 (18). MII, PnIA, and GID were gifts
from J. T. Blanchfield (School of Pharmacy, The University of Queens-
land, Australia), G. Hopping and M. Loughnan (Institute for Molecular
Bioscience, The University of Queensland, Australia), respectively, and
were synthesized as described previously (9, 19, 20).
Homology Modeling—The FASTA format of the 3 and 2 rat se-
quences were retrieved from the ligand-gated ion channel data base
(pasteur.fr/recherche/banques/LGIC/). Their extracellular ligand-bind-
ing domains were aligned with the AChBP sequence as described pre-
viously (21).
A homology model of the 32 nAChR subtype was built on a Silicon
Graphics Octane R12000 work station using the MODELLER program
(22). The AChBP structure (1I9B) was loaded in the INSIGHT II (Ac-
celrys, San Diego, CA) environment and used as a template. Three
models were built with a high “optimize level.” The two options “opti-
mize loop models” and “loop optimize level” were set to 3 and high,
respectively. User disulfide was selected to assign the disulfide bonds as
in AChBP except for the missing vicinal disulfide in the 2 subunit. The
model with the lowest root mean square deviation compared with
AChBP was refined further and used for these studies. Steepest descent
energy minimizations were applied using the AMBER force field and
DISCOVER program implemented in Insight II.
Mutagenesis—Mutagenesis of the 2 nAChR subunit cDNA was
achieved using the QuikChangeTM site-directed mutagenesis kit (Strat-
agene) following the manufacturer’s instructions. Primers used to gen-
erate the mutants were from Proligo (Lismore, Australia). All muta-
tions were confirmed by cDNA sequencing.
Electrophysiological Recordings—cRNA was synthesized from lin-
earized plasmids with SP6 RNA polymerase using the mMessageMa-
chine kit (Ambion, Austin, TX). Xenopus laevis frogs were purchased
from Nasco International (Fort Atkinson, WI) or Firma Ka¨hler (Ham-
burg, Germany). X. laevis oocytes were prepared as described previ-
ously (6) and injected with 50-nl aliquots of cRNA (0.5 g/l).
Two-electrode voltage clamp recordings were performed in oocytes
1–10 days after cRNA injection at a holding potential of 70 mV.
Pipettes were pulled from borosilicate glass and filled with 3 M KCl.
Resistances were below 1 megohm. Membrane currents were recorded
using a Turbo Tec-10CX or a Turbo Tec 05X Amplifier (npi electronic,
Tamm, Germany) filtered at 200 Hz and digitized at 400 Hz. Version
FIG. 1. Homology model of the 32 nAChR showing the loca-
tion of residues mutated in this study. A, ribbon representation of
32 nAChR homology model with mutated residues in stick represen-
tation. B, enlarged view of the molecular surface of the 3/2 subunit
interface showing the relative contribution of both 3 (purple) and 2
(white) subunits to the cleft. Mutated residues are indicated.
FIG. 2. Concentration-response analysis of -conotoxin MII
(A), GID (B), PnIA (C), and [A10L]-PnIA (D) on wild type and
mutant nAChRs. The indicated subunit combinations were expressed
in Xenopus oocytes and analyzed by 2-electrode voltage clamp. Re-
sponses to 2-s pulses of 100 M ACh were recorded after a 3-min
preincubation with the indicated toxin. IC50 values and Hill slopes are
given in Table I. Each point represents the average of at least three
measurements. Error bars represent S.E.
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8.53 Pulse software (HEKA Elektronik, Lambrecht, Germany) or Cell-
Works software were used. The perfusion medium was automatically
switched between ND96 with or without agonist (100 M ACh) using a
custom-made magnetic valve system. A fast and reproducible solution
exchange (300 ms) for agonist application was achieved using a 50-l
funnel-shaped oocyte chamber combined with a fast solution flow (150
l/s) fed through a custom-made manifold mounted immediately above
the oocyte. ACh pulses were applied for 2 s at 4-min intervals. After
each application, the cell was superfused for 1 min with agonist-free
solution, and the flow was then stopped for 3 min. Peptide was mixed
from a 10-fold stock into the static bath when responses to three
consecutive agonist applications differed by less than 10%. Addition of
toxin directly to the recording chamber conserved material and avoided
adhesion of the toxin to tubing surfaces. To obtain estimates of potency,
dose-response curves were fit to the data by the equation % response 
100/{1  ([toxin]/IC50)
nH} using Prism software (GraphPad version 3.0
for Macintosh, San Diego, CA). To obtain estimates of toxin dissociation
rates, agonist responses were measured at 2-min intervals under con-
stant superfusion, and after stabilization of responses, oocytes were
incubated with toxin in a static bath for 1 min. To obtain estimates of
the toxin association rate, oocytes were continuously superfused with
solution containing the indicated toxin concentration and ACh pulses
were applied in 1- or 2-min intervals. Association and dissociation
curves were fit to the data by the equations % response  (100 
plateau)  eK  time  plateau and % response  span (1  eK  time) 
plateau, respectively.
Docking Experiments—Docking simulations of -conotoxins were
carried out as described in Dutertre et al. (17). Briefly, MII and PnIA
structures were retrieved from the protein data bank (Protein Data
Bank codes 1MII and 1PEN, respectively) and docked onto an 32
homology model using the program GOLD, version 1.2 (Genetic Opti-
mization for Ligand Docking, Cambridge Crystallographic Data Centre,
Cambridge, UK). One NMR/crystal structure was chosen for each
-conotoxin, as GOLD treats ligands as flexible molecules with side
chain orientations optimized during calculations. As conotoxins are
competitive antagonists, the active site radius was set at 20 Å from
TABLE I
IC50 values and 95% confidence interval for -conotoxins on wild type and mutant nAChR combinations
-Conotoxins IC50 Hill slope
nM

32 6.08 (4.87–7.61)b 1.38 (0.94–1.83)
32F117A 4.66 (3.59–6.05) 1.04 (0.80–1.27)
32V109A 3.98 (3.58–4.43) 1.22 (1.10–1.33)
32V109G 4.61 (3.70–5.75) 1.29 (1.01–1.56)
32L119Q 1,810 (1,380–2,380) 0.99 (0.73–1.25)
GID
32 5.09 (4.17–6.22) 1.60 (1.11–2.10)
32F117A 3.52 (2.81–4.42) 1.29 (0.90–1.68)
32V109A 4.91 (4.39–5.48) 1.52 (1.26–1.78)
32V109G 3.72 (3.27–4.22) 1.45 (1.18–1.71)
32L119Q 839.20 (752.8–935.5) 0.90 (0.79–1.01)
PnIA
32 7.74 (6.79–8.81) 0.85 (0.74–0.97)
32F117A 7.81 (6.71–9.08) 0.93 (0.79–1.07)
32V109A 10.12 (7.11–14.43) 1.06 (0.64–1.47)
32V109G 34.39 (26.47–44.68) 0.86 (0.60–1.12)
32L119Q 295.80 (177.3–493.6) 0.88 (0.54–1.23)
	A10L
PnIA
32 55.23 (50.69–60.18) 1.09 (0.95–1.23)
32F117A 3.99 (3.14–5.06) 1.03 (0.75–1.31)
32V109A 3.00 (2.73–3.31) 1.19 (1.04–1.33)
32V109G 2.40 (1.95–2.96) 1.36 (0.97–1.75)
MII
42 548.40 (400.6–750.7) 0.97 (0.69–1.25)
42F117A 45.46 (31.38–65.84) 1.10 (0.72–1.49)
GID
42 390.00 (340.9–446.1) 1.31 (1.09–1.54)
42F117A 58.73 (44.52–77.48) 1.35 (0.83–1.87)
PnIA
42 1000 NDa
42F117A 1000 ND
42V109A 1000 ND
42V109G 1000 ND
	A10L
PnIA
42 1000 ND
42F117A 1000 ND
42V109A 1000 ND
42V109G 131.60 (101.4–170.9) 1.07 (0.78–1.36)
a ND, not determined.
b 95% confidence interval values are shown in parentheses.
TABLE II
Off-rate constants of -conotoxins at wild type
and mutant nAChR combinations
-Conotoxins koff
min1

32 0.07 (0.04–0.1)b
32F117A NDa (8.9  0.7% recovery in 20 min)
32V109A ND (11.4  2.6% recovery in 20 min)
32V109G ND (14.1  2.5% recovery in 20 min)
GID
32 0.19 (0.15–0.22)
32F117A ND (15.2  3.0% recovery in 20 min)
32V109A 0.09 (0.06–0.12)
32V109G 0.03 (0.01–0.05)
PnIA
32 ND (100% recovery in 2 min)
32F117A ND (100% recovery in 4 min)
32V109A ND (100% recovery in 4 min)
32V109G ND (100% recovery in 2 min)
	A10L
PnIA
32 ND (100% recovery in 2 min)
32F117A 0.09 (0.07–0.11)
32V109A 0.12 (0.09–0.15)
32V109G ND (13.2  3.3% recovery in 20 min)
a ND, not detectable.
b 95% confidence interval values are shown by numbers in parentheses.
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Trp-147 to ensure the analysis focused on residues around the ACh
binding site. From the 100 docked structures obtained for each cono-
toxin, the selection of the final docked structure was based on a low
scoring function determined in GOLD (23).
RESULTS AND DISCUSSION
Homology Modeling Identifies Val-109, Phe-117, and Leu-
119 in the 2 nAChR Subunit as Likely Residues Interacting
with -Conotoxins MII and PnIA—We previously identified two
cavities at opposite sides of the 9/10 hairpin (C-loop of an 
subunit) on the surface of the nAChR, one large and easily
accessible and one small and narrow, from which the ACh
binding site could be reached (21). To differentiate between
these two cavities and avoid confusion, we propose the use of
“cavity” to refer to the larger one (below the 910 hairpin,
close to the cell membrane), and “cleft” to refer to the smaller
one (above the 910 hairpin). The cavity has recently been
confirmed to represent the binding site used by the large snake
neurotoxins to block the nAChR (24), whereas the cleft repre-
sents the likely region targeted by -conotoxins (17, 21). Dock-
ing simulations with ImI and PnIB structures on an 7 nAChR
model revealed overlapping but different binding sites for
-conotoxins and snake toxins (17). Both -conotoxins block the
receptor by targeting a small cleft above the 9/10 hairpin that
is also blocked by the small peptide antagonist toxin waglerin
(25) and the non-peptidic antagonist d-tubocurarine (26). Con-
cerning the 32 nAChR, only one residue (2-Thr-57) weakly
affecting 4/7 conotoxin binding has been identified on the 2
subunit compared with four on the 3 subunit (27, 28). Inter-
estingly, 2-Thr-57 is located above the 910 hairpin, forming
part of the cleft in 32 together with three other residues,
Val-109, Phe-117, and Leu-119. A potentially important role for
additional residues in the  subunit is suggested from binding
kinetic studies where exchange of the 2 subunit by the 4
subunit (in combination with 3 or 6 subunits) strongly re-
duced the off-rate constants of PIA (29). Likewise, BuIA
showed much slower dissociation if 2, 3, 4, or 6 subunits
are combined with 4 instead of 2 (30). In an attempt to
identify additional determinants in the  subunit that contrib-
ute to the binding and selectivity of 4/7 -conotoxins, we mu-
FIG. 3. Off-rate kinetics of -conotoxins MII (A), GID (B), PnIA
(C), and [A10L]-PnIA (D) on wild type and mutant nAChRs.
Responses to 2-s pulses of ACh after a 90–100% block by the indicated
toxins were recorded at 2-min intervals during continuous superfusion.
Off-rate constants are given in Table II. Each point represents the
average of at least three measurements. Error bars represent S.E.
FIG. 4. Experimentally determined on-rate kinetics and calcu-
lated off-rate constant of -conotoxin MII at the 32F117A
mutant nAChR. A, the indicated concentrations of MII were applied
by continuous perfusion to oocytes expressing the 32F117A mutant,
and responses to 2-s pulses of ACh were monitored at 1- or 2-min
intervals. The faster on-rate kinetics of MII at the wild type 32
receptor is shown for comparison. B, experimentally determined on-rate
constants were plotted against the toxin concentration to obtain an
estimate of the off-rate constant and the Ki value. F in the formula
indicates the free toxin concentration. Each point represents the aver-
age of at least three measurements. Error bars represent S.E.
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tated Leu-119, which appears deep in the cleft, as well as
Phe-117 and Val-109, which form part of the wall of the cleft
(Fig. 1).
Residue Leu-119 Is Generally Important for -Conotoxin
Binding—A leucine in position 2-119 lies at the bottom of the
cleft and is conserved in neuronal 4 and 7 nAChR subunits
as well as in the muscle , , and  nAChR subunits. Thus, a
leucine is present at this location in all non- subunits (and the
() face of the 7 nAChR) for which highly active -conotoxins
have been identified. Indeed, no potent -conotoxin has been
found for the 9 and 10 subunits, which have a negatively
charged aspartic acid at this position. In combination with the
docking studies, this suggests that the hydrophobic environ-
ment created by 2-Leu-119 and the corresponding leucine
residues in other subunits plays an important role in the high
affinity interaction with -conotoxins. To test the hypothesis
that Leu-119 is generally important for -conotoxin binding,
the activity of three different -conotoxins that bind with high
affinity to the 32 nAChRs was tested on the hydrophilic
32-L119Q mutant. The 32/62-selective -conotoxin MII
as well as the 32/7-selective -conotoxins PnIA and GID
had a strongly reduced activity (Fig. 2, A–C), with 40-fold
(PnIA), 165-fold (GID), and 300-fold (MII) higher IC50 values at
this mutant 32 receptor (Table I). This is the strongest effect
described thus far for a non- subunit mutant affecting -cono-
toxin binding. Based on its position at the bottom of the cleft
and the fact that the activity of all three conotoxins was re-
duced by at least 40-fold upon introduction of a similar length
hydrophilic residue (Gln), Leu-119 may play an important sta-
bilizing role for the interaction with -conotoxins, allowing
them to bind deep into the nAChR cleft.
In addition to the four cysteines, which are involved in two
disulfide bonds and are mostly buried within the peptide core,
only serine and proline residues are common to all three
-conotoxins. Because mutation of Ser-4 in MII did not affect
potency (31), we suspect that Leu-119 might interact with the
-conotoxin backbone or the conserved proline found in 4/7
-conotoxins (third residue of loop 1). However, this possibility
is difficult to test by double mutant cycle analysis because
alteration of the conserved cysteine or proline residues in the
conotoxin alters the peptide backbone conformation.
Alanine Exchange of Val-109 and Phe-17 Specifically En-
hances Binding of MII and GID—In our model of the 2 sub-
unit, residues Val-109 and Phe-117 lie adjacent to each other
on two neighboring antiparallel -strands and above the Leu-
119 residue, potentially forming the walls of the -conotoxin
binding cleft (Fig. 1). By mutating the residues into the smaller
alanine, we expected to weaken the interaction with -conotox-
ins. Unexpectedly, both the F117A and V109A mutations pro-
duced IC50 values for MII, GID, and PnIA little different from
those at the wild type receptor, suggesting that Phe-117 and
Val-109 do not have close interactions with the -conotoxins
FIG. 5. Activity of -conotoxins MII
and GID (A) and PnIA and
[A10L]PnIA (B) on wild type and mu-
tant 42 nAChRs. The indicated sub-
unit combinations were expressed in Xe-
nopus oocytes, and responses to 2-s pulses
of 100 M ACh were recorded after a
3-min preincubation with different con-
centrations of the indicated toxin. IC50
values and Hill slopes are given in Table
I. Each point represents the average of at
least three measurements. Error bars
represent S.E.
FIG. 6. Sequence comparison of
-conotoxins acting at the 32
nAChR. A, although MII and GID show
an enhanced binding at the 32V109A/G
and F117A mutants, the binding of PnIA
appeared unchanged. Residues common
to PnIA and MII and/or GID are marked
in gray. Residues indicated by arrows
could account for the observed differ-
ences. B, L10A exchange in PnIA en-
hanced binding of PnIA at the mutants,
indicating that a long or bulky aliphatic
side chain in position 10 conferred a
strong interaction with the 2-F117A and
2-V109G/V109A mutants.
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(Fig. 2, A–C, Table I). The same effect was observed for V109G
(except for PnIA, where a slight decrease in affinity was ob-
served). However, the off-rates of MII were affected by all three
mutations (Table II), resulting in a very slowly reversible block
by MII (Fig. 3A). A similar effect on the binding was observed
with GID (Fig. 3B). In contrast, the off-rates of PnIA appeared
to be hardly affected by the mutations (Fig. 3C). The finding
that alanine exchange of Val-109 or Phe-117 decreased the
off-rate constants of MII and GID without an obvious change in
the IC50 value implied that a similar reduction in on-rate had
occurred to balance the off-rate change or that the IC50 value
had not been determined accurately because of the short 3-min
preincubation times. To obtain a more accurate estimate of the
potency, on-rates of MII binding to the wild type and F117A
mutant were compared. As expected, the F117A mutant dis-
played a much slower on-rate for MII compared with its on-rate
at the wild type receptor (Fig. 4A). Calculated on- and off-rates
for MII at the 32F117A mutant produced a Ki value of 0.69
nM (Fig. 4B),  10-fold lower than the experimentally deter-
mined IC50 value (Fig. 2A, Table I). Unfortunately, the long
incubation times necessary to determine the real IC50 values at
the 32F117A and Val-109 mutants were not practical be-
cause of run-up/down effects on nAChR current seen in oocytes
and the large amounts of toxin needed for superfusion. There-
fore, to complement the IC50 value determinations, we com-
pared off-rates as a measure of toxin affinity that is independ-
ent of toxin concentration or preincubation time. Because not
only the off-rate constants but also the on-rate constant of GID
and MII on the Val-109 and Phe-117 mutants were decreased,
we propose that these residues comprise part of a short access
path or an intermediate binding state that -conotoxins tran-
sition past before reaching (or leaving) their high affinity
bound state.
The Effect on Val-109 and Phe-117 Exchange Also Occurs in
Combination with the 4 nAChR Subunit—The results pre-
sented above show that a small modification of the 2 subunit
can have a strong and specific effect on conotoxin binding,
suggesting that the  subunit contributes to -conotoxin bind-
ing through direct and specific interactions. However, it cannot
be excluded that this is a secondary effect because of an alter-
ation in the conformation of the  subunit induced by the
mutation in the  subunit. To address this aspect, we investi-
gated whether these 2 effects were preserved in combination
with a different  subunit. Both MII and GID showed nanomo-
lar activity at the 42 nAChR subtype, whereas no activity
was observed for PnIA at concentration up to 1 M. When the
4 subunit was combined with the 2-F117A mutation, both
GID and MII showed an 10-fold increase in activity (Fig. 5A)
that was likewise paralleled by a clearly decreased off-rate
(results not shown). This further indicates that the binding
modes of MII and GID within the binding pocket are conserved
across the 42 and 32 receptor interfaces and that the 
subunit contributes directly to -conotoxin potency. Whereas
the overall higher IC50 values at the 42 combination suggest
that the contribution of the 4 subunit to conotoxin binding is
smaller than that of the 3 subunit, the inactivity of PnIA could
also be explained by a residue in PnIA that prevents an inter-
action with the 4 subunit.
The Length of the Side Chains in Position 10 of the -Cono-
toxins Determines the Strength of the Interaction with the Val-
109 and Phe-117 Mutants—Sequence comparison of PnIA with
MII and GID (Fig. 6) shows that there are 7 residues in PnIA
(Leu-5, Pro-7, Ala-7, Ala-10, Pro-13, Asp-14, and Tyr-15), which
are different from the corresponding residues in GID or MII
and thus are likely candidates to account for the poor activity of
PnIA at the 42 interface and the low affinity of PnIA (com-
pared with GID and MII) at the 32 mutants. Because MII
has a leucine and PnIA an alanine at position 10, it appears
that a long or bulky aliphatic side chain enhances -conotoxin
FIG. 7. Molecular surface complementarities for -conotoxins
and the 32 cleft. Molecules are shown at the same scale, allowing
direct size comparison and shape complementarity between -conotox-
ins and the nAChR cleft. -Conotoxins PnIA and MII are shown with
their N-terminal sequences facing the reader. The contour of the cleft
was flipped 180° to allow a direct comparison with the -conotoxin
shapes. This figure was produced using MOLCAD in Sybyl7.0 (Tripos
software, St. Louis, MO).
FIG. 8. Docking of PnIA (A) and MII -conotoxins (B) onto the
32 nAChR. Each of these conotoxins penetrated deep into the cleft
with its conserved N-terminal hydrophobic patch, which includes the
conserved Pro-6. Toxin residues make contacts with both the 3 and 2
subunits. The C-terminal part of both conotoxins protrudes beyond the
cleft.
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interactions with the Phe-117 and Val-109 mutants. To further
test this hypothesis, we investigated the activity of the A10L-
PnIA analogue on both 32 and 42 mutants. As predicted,
replacing Ala-10 by a longer leucine residue enhanced PnIA
affinity for 2 receptors containing the Phe-117 or Val-109
mutations (Figs. 2D and 3D; Tables I and II). Indeed, a mark-
edly reduced off-rate constant and an up to 23-fold lower IC50
value were observed for A10L-PnIA at the 2 mutants (Table I:
3.99 nM on 2-F117A; 3 nM on 2-V109A; 2.4 nM on 2-V109G)
compared with the wild type 32 receptor (55 nM). Moreover,
this A10Lmodification converted PnIA into a potent antagonist
at the 42-V109G receptor (Fig. 5B).
Residue 10 in PnIA has previously been shown to be an
important determinant of selectivity between 32 and 7
receptors (8). A comparison of a range of conotoxins with se-
quence similarity in the second loop showed that the length of
the side chain in position 10 correlated with an 7 versus 32
selectivity. This correlation was also found to be valid for GID
and PnIA but not for MII, suggesting that MII has an altered
binding mode. However, the similar influence of 2 mutants on
GID, PnIA, and MII affinity indicate that these 4/7 -conotox-
ins orientate similarly within the cleft formed by the / inter-
face and that the critical position 10 side chain likely faces the
2 subunit in all three -conotoxins.
Shape and Size Complementarity between 4/7 -Conotoxins
and the Cleft in nAChRs—A high affinity complex requires
either a large contact area between receptor and ligand sur-
faces with multiple points of interaction or shape complemen-
FIG. 9. -Conotoxin and 2 subunit
pharmacophores. PnIA (A) and MII (B)
conotoxins are presented in their docked
orientation in the cleft (C). The minimal
pharmacophore shown is consistent with
mutagenesis results and previous -cono-
toxin alanine scan data. Distances (Å) be-
tween residues are measured from the
last carbon of the side chain and reported
on the vectors in the right-hand panels.
Also shown are the equivalent residues
for the 3 (green), 4 (blue), and () 7
(red) subunits. Note that Phe-117 is posi-
tioned under Glu-59.
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tarity that favors the formation of a smaller number of specific
interactions (e.g. a ligand bound in a protein cleft). Given their
relatively small size, the high affinity complex observed for
-conotoxins suggests that a tight fit between the -conotoxin
and a cleft on the nAChR surface is likely to occur. The 7
nAChR cleft appears to be 7 Å deep, 13.5 Å long, and 9.5 Å
wide (6.6 Å at the narrowest point). These dimensions are
almost identical to those found for the 32 nAChR (7.5 Å deep,
14.5 Å long, and 9.8 Å wide (6.8 Å at the narrowest)), and are
mostly conserved in shape. For comparison, we measured the
dimensions of the N-terminal hydrophobic patch of -conotox-
ins. In MII it is 12 Å long (Gly- to Val-7) and 7 Å wide, and in
PnIA it is 11.2 Å long (Gly-1 to Pro-7) and 6.5 Å wide, whereas
GID has a flexible tail that complicates the measurements (a
tail-truncated analogue has similar dimension to PnIA and
MII, and the tail could be accommodated by the flexible loop F
of nAChR). These comparisons reveal a striking size and shape
complementarity between 4/7 -conotoxins and the nAChR
cleft, strongly suggesting a lock-and-key interaction (Fig. 7).
Docking Models of PnIA and MII Interactions with 32
nAChR—To verify that 4/7 -conotoxins can interact with the
nAChR cleft via their conserved hydrophobic patch (residues 6,
7, and 10), docking of PnIA and MII structures onto an 32
nAChR model were simulated using the program GOLD. Anal-
ysis of the results from docking simulations confirmed both
hypotheses: the small cleft is the binding site for 4/7 -cono-
toxins, and the -conotoxins bind to the 32 nAChR by pre-
senting their conserved N-terminal shape (Fig. 7). Indeed, al-
though an active site radius set to 20 Å would have allowed
ligands to dock at other locations around the C-loop, all struc-
tures were found docked in the cleft above the 9/10 hairpin.
The final orientation of PnIA and MII docked into the receptor
cleft presented in Fig. 8 was chosen from the cluster of lowest
energy structures produced by GOLD and on the basis of how
well it fitted the available experimental data. Both -conotox-
ins bind in a similar way to the docking mode found for PnIB at
the 7 nAChR (17). It is interesting to note that although MII
still binds to 32 from its hydrophobic patch similarly to
PnIA, its position in the cleft appears slightly shallower com-
pared with PnIA, as expected given the greater width of its
C-terminal half (see Fig. 7). Interestingly, MII is observed to
make additional contacts with 32 nAChR residues, giving an
explanation for its very slow off-rate and associated higher
affinity compared with PnIA. Indeed, although 2-L119 ap-
pears in close proximity to the conserved P6 residue, and posi-
tion 10 residues are found between 2-V109 and 2-F117 in
both PnIA and MII, only His-9 of MII makes an electrostatic
interaction with 2-Glu-57 possible. However, the hydrophobic
interaction between -conotoxins (positions 6, 7, and 10) and
the nAChR cleft (Leu-119, Val-109 and Phe-117) appears to
play a significant role in the high affinity complex observed.
Mutagenesis experiments carried out by others have identified
5 residues influencing MII and PnIA binding (27, 28). Although
2-Thr-57 is located in the cleft, and 3-Ile-183 is in close
proximity of both docked structures, residues Lys-183, Pro-180,
and Gln-196 are far from the binding site. We propose that
their effect on peptide binding is likely to be indirect, as they
are all located on the structurally important 9/10 hairpin and
include two proline mutants (P180T and Q196P), expected to
have a significant structural effect. The orientation of 4/7
-conotoxins in the cleft explains the functional data obtained
from the 2 mutants.
Pharmacophore—We developed a minimal antagonist phar-
macophore for 4/7 -conotoxins based on our mutagenesis and
docking results (Fig. 9). PnIA has a very hydrophobic N-termi-
nal patch, comprising Leu-5, Pro-6, Pro-7, Ala-9, and Ala-10
(Fig. 9A). MII also possesses a similar hydrophobic core (Pro-6,
Val-7, and Leu-10) that we take to represent a minimum an-
tagonist pharmacophore (Fig. 9B). When compared with the 2
subunit pharmacophore (Fig. 9C), the distances found in cono-
toxins are compatible with the direct interaction between the
conserved proline in position 6 and 2-Leu-119 that we ob-
served in our docking model. We propose that Pro-6 in 4/7
conotoxin acts as an anchor and stabilizes the conotoxin-recep-
tor complex. Additional hydrophobic contacts such as Pro-7
(PnIA) or Val-7 (MII) and Ala-10 (PnIA) or Leu-10 (MII) with
2-Val-109 and 2-Phe-117 strengthen the interaction,
whereas secondary interactions such as His-9 (MII) and 2-
Glu-57 determine the selectivity. A comparison of residues in
the equivalent position of the receptor pharmacophore in other
 subunits and () 7 reveals important differences likely to
influence -conotoxin selectivity (Fig. 9C). For example, the
polar Thr-119 residue present in 3 may explain the absence of
-conotoxins acting at nAChRs containing this subunit.
Conclusions—We have demonstrated the predictiveness of
nAChR homology models based on the AChBP structure and
characterized a small cleft as the common binding site for 4/7
-conotoxins. Point mutations in this cleft revealed a major
effect of 2-Leu-119 on -conotoxin affinity and important in-
fluences of 2-Phe-117 and 2-Val-109 on -conotoxin binding
kinetics. Furthermore, we could demonstrate a specific inter-
action of residue 10 in -conotoxins with the 2 subunit. Dock-
ing simulations of PnIA and MII at 32 confirmed these
results by showing a direct interaction between 2 and -cono-
toxin residues. These studies indicate that -conotoxins block
the nAChRs by a lock-and-key interaction, where a primary
hydrophobic interaction between 2-Leu-119 and the con-
served Pro of 4/7 -conotoxins “locks” the ligand in its cleft, and
secondary complementary interactions contribute to ligand se-
lectivity. Based on homology models of nAChRs, the identifica-
tion of ligand-accessible residues in the cleft (Leu-119, Val-109,
and Phe-117) and the determination of a minimal antagonist
pharmacophore, a rational approach to the design of subtype-
selective nAChR modulators can now be pursued.
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Note Added in Proof—Our studies on 4/7 -conotoxin binding mode at
mammalian nAChRs are strikingly similar to the binding mode deter-
mined for 4/7 -conotoxins co-crystallized with AChBP (Celie, P. H.,
Kasheverov, I. E., Mordvintsev, D. Y., Hogg, R. C., van Nierop, P., van
Elk, R., van Rossum-Fikkert, S. E., Zhmak, M. N., Bertrand, D., Tsetlin,
V., Sixma, T. K., and Smit, A. B. (2005)Nat. Struct. Mol. Biol., in press),
revealing a remarkable conservation of -conotoxin binding to nAChRs
across different species and subtypes. Interestingly, AChBP has a Met
instead of the equivalent Leu-119 in 2 that contributes to the binding
of -conotoxins.
REFERENCES
1. McIntosh, J. M., Santos, A. D., and Olivera, B. M. (1999) Annu. Rev. Biochem.
68, 59–88
2. Nicke, A., Wonnacott, S., and Lewis, R. J. (2004) Eur. J. Biochem. 271,
2305–2319
3. Kuryatov, A., Olale, F., Cooper, J., Choi, C., and Lindstrom, J. (2000) Neuro-
pharmacology 39, 2570–2590
4. Vailati, S., Hanke, W., Bejan, A., Barabino, B., Longhi, R., Balestra, B.,
Moretti, M., Clementi, F., and Gotti, C. (1999) Mol. Pharmacol. 56, 11–19
5. Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins,
A. C., and Grady, S. R. (2004) Mol. Pharmacol. 65, 1526–1535
6. Quik, M., Polonskaya, Y., Kulak, J. M., and McIntosh, J. M. (2001) J. Neurosci.
21, 5494–5500
7. Luo, S., Nguyen, T. A., Cartier, G. E., Olivera, B. M., Yoshikami, D., and
McIntosh, J. M. (1999) Biochemistry 38, 14542–14548
8. Hogg, R. C., Miranda, L. P., Craik, D. J., Lewis, R. J., Alewood, P. F., and
Adams, D. J. (1999) J. Biol. Chem. 274, 36559–36564
9. Nicke, A., Loughnan, M. L., Millard, E. L., Alewood, P. F., Adams, D. J., Daly,
2 nAChR Subunit Contributes to -Conotoxin Binding 30467
N. L., Craik, D. J., and Lewis, R. J. (2003) J. Biol. Chem. 278, 3137–3144
10. Hill, J. M., Oomen, C. J., Miranda, L. P., Bingham, J. P., Alewood, P. F., and
Craik, D. J. (1998) Biochemistry 37, 15621–15630
11. Hu, S. H., Gehrmann, J., Guddat, L. W., Alewood, P. F., Craik, D. J., and
Martin, J. L. (1996) Structure 4, 417–423
12. Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J.,
Smit, A. B., and Sixma, T. K. (2001) Nature 411, 269–276
13. Le Novere, N., Grutter, T., and Changeux, J. P. (2002) Proc. Natl. Acad. Sci.
U. S. A. 99, 3210–3215
14. Schapira, M., Abagyan, R., and Totrov, M. (2002) BMC Struct. Biol. 2002 2, 1
15. Fruchart-Gaillard, C., Gilquin, B., Antil-Delbeke, S., Le Novere, N., Tamiya,
T., Corringer, P. J., Changeux, J. P., Menez, A., and Servent, D. (2002) Proc.
Natl. Acad. Sci. U. S. A. 99, 3216–3221
16. Samson, A., Scherf, T., Eisenstein, M., Chill, J., and Anglister, J. (2002)
Neuron 35, 319–332
17. Dutertre, S., Nicke, A., Tyndall, J. D., and Lewis, R. J. (2004) J. Mol. Recognit.
17, 339–347
18. Gloor, S., Pongs, O., and Schmalzing, G. (1995) Gene 160, 213–217
19. Blanchfield, J. T., Dutton, J. L., Hogg, R. C., Gallagher, O. P., Craik, D. J.,
Jones, A., Adams, D. J., Lewis, R. J., Alewood, P. F., and Toth, I. (2003)
J. Med. Chem. 46, 1266–1272
20. Hogg, R. C., Hopping, G., Alewood, P. F., Adams, D. J., and Bertrand, D. (2003)
J. Biol. Chem. 278, 26908–26914
21. Dutertre, S., and Lewis, R. J. (2004) Eur. J. Biochem. 271, 2327–2334
22. Sali, A., and Blundell, T. L. (1993) J. Mol. Biol. 234, 779–815
23. Jones, G., Willett, P., Glen, R. C., Leach, A. R., and Taylor, R. (1997) J. Mol.
Biol. 267, 727–748
24. Bourne, Y., Talley, T. T., Hansen, S. B., Taylor, P., and Marchot, P. (2005)
EMBO J., in press
25. Molles, B. E., Tsigelny, I., Nguyen, P. D., Gao, S. X., Sine, S. M., and Taylor,
P. (2002) Biochemistry 41, 7895–7906
26. Gao, F., Bern, N., Little, A., Wang, H. L., Hansen, S. B., Talley, T. T., Taylor,
P., and Sine, S. M. (2003) J. Biol. Chem. 278, 23020–23026
27. Everhart, D., Reiller, E., Mirzoian, A., McIntosh, J. M., Malhotra, A., and
Luetje, C. W. (2003) J. Pharmacol. Exp. Ther. 306, 664–670
28. Harvey, S. C., McIntosh, J. M., Cartier, G. E., Maddox, F. N., and Luetje, C. W.
(1997) Mol. Pharmacol. 51, 336–342
29. Dowell, C., Olivera, B. M., Garrett, J. E., Staheli, S. T., Watkins, M., Kuryatov,
A., Yoshikami, D., Lindstrom, J. M., and McIntosh, J. M. (2003) J. Neurosci.
23, 8445–8452
30. Azam, L., Dowell, C., Watkins, M., Stitzel, J. A., Olivera, B. M., and McIntosh,
J. M. (2005) J. Biol. Chem. 280, 80–87
31. Everhart, D., Cartier, G. E., Malhotra, A., Gomes, A. V., McIntosh, J. M., and
Luetje, C. W. (2004) Biochemistry 43, 2732–2737
2 nAChR Subunit Contributes to -Conotoxin Binding30468
